Zolandronic acid protective effect on bone loss in postmenopausal women switched from tamoxifen to letrozole in the treatment of early breast cancer.

Safra, Tamar; Bernstein, Rebecca; Stephansky, I.; Yaal‐Hahoshen, Neora; Inbar, Moshe; Ackerstein, Aliza; Geffen, D.

doi:10.1158/0008-5472.sabcs-1153

Public

Zolandronic acid protective effect on bone loss in postmenopausal women switched from tamoxifen to letrozole in the treatment of early breast cancer.

Shared by NobleBlocks on Jan 1, 2009 • 12:00 AM UTC

Authors:

Tamar Safra

Rebecca Bernstein

I. Stephansky

Abstract

Abstract Abstract #1153 BACKGROUND: Adjuvant treatment with aromataze inhibitors (AI's) in postmenopausal women (PMW) with early breast cancer (BC) can be associated with decreased bone mineral density (BMD) and increase risk of osteoporosis and fractures. Tamoxifen on the contrary, increases BMD, a...

Subject

Letrozole

Medicine

Tamoxifen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!